Symptomatic treatment of vertigo, iterative with or without cochlear sign


The usual dosage is 1 to 2 tablets 3 times daily, preferably in the middle of meals, not to exceed 6 tablets, or 48 mg, of betahistine per day. Br>
Children and adolescents

The use of BETAHISTINE RPG 8 mg in children and adolescents under 18 years of age is not recommended due to lack of data, safety and efficacy < Br>

Elderly subjects

Since the available data are limited, betahistine should be used with caution in the elderly.

There is no data available in patients with renal insufficiency

Hepatic impairment

There is no data available in patients with hepatic impairment

Duration of processing

The duration of the recommended treatment is 2 to 3 months, to be renewed, possibly, depending on the course of the disease, in continuous or discontinuous cures. >
Mode of administration

The tablets must be swallowed without being chewed with a glass of water during meals


(N: nervous system, central).
The mechanism of action of betahistine is partially known.

In vitro, betahistine facilitates histaminergic transmission by its partial agonist effect on H 1 receptors and an antagonistic effect of H 3 receptors.
< Code>
Betahistin decreases, electrical activity of polysynaptic neurons, vestibular nuclei after I.V. administration in the animal

Betahistine has no effect sedative

Not applicable.

· Hypersensitivity to any of the components of this drug

· Gastroduodenal ulcer in thrust

· Pheochromocytoma.


In asthmatics, administration of betahistine requires special surveillance (risk of bronchoconstriction).

Precautions for use

Taking medication in the middle of meals helps avoid gastralgia

Not applicable.

Not applicable.

Symptoms analogous to those caused by histamine

Administer antihistamine treatment


Studies in the animal have not demonstrated any teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals during studies, well conducted on two species
< Br>

There is at present no relevant or sufficient data to evaluate a possible malformative or fetotoxic effect of betahistin when administered during pregnancy

Therefore, as a precautionary measure, it is preferable not to use betahistin during pregnancy.

In the absence of data on the passage through breast milk, the risk is not known, therefore breast-feeding is not recommended, while taking betahistine.

Most common adverse reactions

Gastralgia, nausea, vomiting, dry mouth, diarrhea. More rarely, headache, asthenia, somnolence, hypersensitivity reactions.


Thrombocytopenia, elevation of transaminases.

Symptomatic treatment of vertigo, iterative with or without cochlear sign